Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA:600329)

China flag China · Delayed Price · Currency is CNY
43.01
-0.19 (-0.44%)
At close: Feb 27, 2026
43.22%
Market Cap 29.42B
Revenue (ttm) 5.37B
Net Income (ttm) 3.58B
Shares Out 770.09M
EPS (ttm) 4.66
PE Ratio 9.23
Forward PE 14.24
Dividend 1.28 (2.98%)
Ex-Dividend Date Feb 12, 2026
Volume 2,797,027
Average Volume 5,672,277
Open 43.20
Previous Close 43.20
Day's Range 42.72 - 43.22
52-Week Range 28.53 - 50.97
Beta 0.78
RSI 40.56
Earnings Date Mar 31, 2026

About SHA:600329

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Li... [Read more]

Sector Healthcare
Founded 1981
Employees 4,619
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600329
Full Company Profile

Financial Performance

In 2024, SHA:600329's revenue was 7.31 billion, a decrease of -11.14% compared to the previous year's 8.22 billion. Earnings were 2.23 billion, an increase of 125.94%.

Financial Statements

News

There is no news available yet.